US Stock Insider Trading | Tectonic disclosed 1 insider transaction on February 11

2026-02-22 17:47:20

On February 11, 2026, Tectonic (TECX) disclosed an insider transaction. Executive Lochner Daniel purchased 6,000 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 11, 2026	Executive	Lochner Daniel	February 10, 2026	Buy	6,000	21.61	$129,700
February 10, 2026	Director	REICIN ALISE	February 4, 2026	Sell	4,104	23.22	$95,300
February 10, 2026	Executive	Lochner Daniel	February 4, 2026	Sell	2,077	23.22	$48,200
February 10, 2026	Executive	Ruddy Marcella K.	February 4, 2026	Sell	2,064	23.22	$47,900
February 10, 2026	Executive	McNamara Peter	February 4, 2026	Sell	1,748	23.22	$40,600
February 10, 2026	Executive	Schwabish Marc	February 4, 2026	Sell	1,619	23.22	$37,600
January 5, 2026	Director	REICIN ALISE	December 31, 2025	Buy	11,000	2.38	$26,100
December 29, 2025	Executive	McNamara Peter	December 22, 2025	Buy	7,000	2.98	$20,900
June 24, 2025	Director	REICIN ALISE	June 20, 2025	Sell	859	19.81	$17,000
April 11, 2025	Shareholder with >10%	SPRINGER TIMOTHY A	April 9, 2025	Buy	19,100	14.62	$278,900

[Company Information]

Tectonic Therapeutic, Inc. is a company incorporated under Delaware law. It is a biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein-coupled receptor (“GPCR”) activity. Using its proprietary platform called GEODe (“GPCR Engineered for Optimal Discovery”), Tectonic aims to develop biologics to overcome existing challenges in GPCR-targeted drug discovery and to leverage the human body to alter disease progression. Tectonic focuses on areas with significant unmet medical needs, often where treatment options are limited or nonexistent, as new drugs in these areas have the potential to improve patients’ quality of life.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes